

PTO/GB(04/04-07)

Approved for use through 7/31/2009. CMB 0651-0031
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/598,449
				Filing Date	August 30, 2006
				First Named Inventor	Hamed Aissaoui
				Art Unit	1625
				Examiner Name	Zinna Northington Davis
(Use as many sheets as necessary)					
Sheet	1	of	3	Attorney Docket No: AC-26-US	

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T*
		Official Note 34103 of Instituto Mexicano de la Propiedad Industrial, dated April 28, 2009 in Mexican Patent No. 269553, PA/a/2006/009833, foreign counterpart to present application.	N/A	ACTELION PHARMACEUTICAL LTD	✓
		Response of June 25, 2009 to Official Note 34103 of Instituto Mexicano de la Propiedad Industrial, dated April 28, 2009 in Mexican Patent No. 269553, PA/a/2006/009833, foreign counterpart to present application.	N/A	ACTELION PHARMACEUTICAL LTD	✓

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T*
		SAKURAI T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nature Reviews. Neuroscience, Vol 8; March 2007.			
		SUTCLIFFE J.G. & DE LECEA L. The hypocretins: setting the arousal threshold. Nature Reviews. Neuroscience 3, 339-49; 2002.			
		BRISBARE-ROCH C, FELETTI L, KOBERSTEIN R, NAYLER O, JENCK F. Transient orexin receptor blockade induces sleep without cataplexy in rats, Nature Clinical Practice Neurology, May 2007, Vol. 3, No. 5, pg. 245.			
		JENCK F, FISCHER C, QIU C, HESS P, KOBERSTEIN R, BRISBARE-ROCH C Somnolence induced by pharmacological blockade of both orexin OX1 and OX2 receptors in dogs, Sleep and Biological rhythms 2007, 5, (S1), A79 Poster 271 at the World Sleep Congress, Cairns, September 2007.			

EXAMINER

/Zinna Davis/ (02/16/2010)

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with SUPER 500. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) = Applicant is to place a check mark here if English language translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/

Under the Privacy Protection Act of 1974, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
 Approved for use through 7/31/2009. CMB 0051-0001
 US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE
 PTO/SB/0504-07

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/598,449
				Filing Date	August 30, 2006
				First Named Inventor	Hamed Aissaoui
				Art Unit	1625
				Examiner Name	Zinna Northington Davis
(Use as many sheets as necessary)					
Sheet	2	of	3	Attorney Docket No: AC-26-US	

		HOEVER P, DE HAAS S, WINKLER J, CAVALLARO M, VAN GERVEN J, DINGEMANSE J, Entry-into-humans study with almorexant (ACT-078573), a dual orexin receptor antagonist: tolerability, safety, and pharmacokinetics, Sleep and Biological rhythms 2007,5 (S1): A131, Poster 444 at the World Sleep Congress, Cairns, September 2007.	
		HOEVER P, DE HAAS S, CHIOSSI E, VAN GERVEN J, DINGEMANSE J, Entry-into-humans study with almorexant (ACT-078573), a dual orexin receptor antagonist: pharmacodynamics, Sleep and Biological rhythms 2007,5 (S1): A131, Poster 443 at the World Sleep Congress, Cairns, September 2007.	
		DINGEMANSE J, DORFFNER G, HAJAK G, BENES H, DANKER-HOPFE H, POLO O, SALETU B, BARBANOJ MJ, PILLAR G, PENZEL T, CHIOSSI E, HOEVER P, Proof-of-concept study in primary insomnia patients with almorexant (ACT-078573), a dual orexin receptor antagonist, Sleep and Biological rhythms 2007,5: A194, Poster 653 at the World Sleep Congress, Cairns, September 2007.	
		BRISBARE-ROCH C, DINGEMANSE J, KOBERSTEIN R, HOEVER P, AISSAOUI H, FLORES S, MUELLER C, NAYLER O, VANGERVEN J, DEHAAS S, HESS P, QIU C, BUCHMANN S, SCHERZ M, WELLER T, FISCHLI W, CLOZEL M & JENCK F, Promotion of sleep by targeting the orexin system in rats, dogs and humans, Nature Medicine, 13: 150-155, 2007	
		JENCKF, BRISBARE-ROCH C, FLORES S, KOBERSTEIN R, NAYLER O, DINGEMANSE J, CLOZEL M, Correspondence on "promotion of sleep by targeting the orexin system in rats, dogs and humans", Nature Medicine, 13: 525-526, 2007.	
		BRISBARE-ROCH C, CLOZEL M, JENCK F, Effects of repeated oral administration of the orexin receptor antagonist almorexant in male rats and dogs, Sleep 2008,31: A38 Poster 0118 at the US Associated Professional Sleep Societies meeting, Baltimore, June 2008.	

EXAMINER

/Zinna Davis/ (02/16/2010)

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/

PTO/SB/04-07

Approved for use through 7/31/2009. CMB 0631-0031
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known Application Number 10/598,449 Filing Date August 30, 2006 First Named Inventor Hamed Aissaoui Art Unit 1625 Examiner Name Zinna Northington Davis	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	3	of	3	Attorney Docket No: AC-26-US	

		HOEVER P, DE HAAS S, CHIOSSI E, VAN GERVEN J, DINGEMANSE J, Multiple-dose pharmacokinetics, pharmacodynamics, safety, and tolerability of the orexin receptor antagonist almorexant in healthy subjects. Sleep 2008;31: A38 Poster 0116 at the US Associated Professional Sleep Societies meeting, Baltimore, June 2008.	
		JENCK F., BRISBARE-ROCH C, AISSAOUI H, KOBERSTEIN R, Promotion of sleep through an orally available hypocretin/orexin antagonist in rats, dogs and humans, Eur Neuropsychopharm 2008;18 (Suppl4): S158, Lecture at the European College of Neuropsychopharmacology (ECNP) meeting, Barcelona, September 2008.	
		FURLONG TM, DANIEL M. L.VIANNA, LU LIU AND PASCAL CARRIVE, Extramural: Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal European Journal of Neuroscience, 2009, AOP: Oct 7, 2009	
		HOCH M, HOEVER P, HASCHKE M, KRÄHENBÜHL S, ALESSI F, DINGEMANSE J, Biocomparison of two formulations of almorexant, a dual orexin receptor antagonist, including investigation of food effect, Poster at American College of Clinical Pharmacology, 38th Annual Meeting, San Antonio, Texas, September 13-15, 2009	
		JAE-EUNKANG, MIRANDA M. LIM, RANDALL J. BATEMAN, JAMES J. LEE, LIAM P.SMYTH, JOHN R. CIRRITO, NOBUHIROFUJIKI, SEIJI NISHINO, DAVID M. HOLTZMAN, Extramural: Amyloid- β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle, ScienceExpress, 24 September 2009	

EXAMINER

/Zinna Davis/ (02/16/2010)

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP § 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's action in response to this communication is required to place a check mark beside English language translation of a reference.

ALL REFERENCES WERE ACTION CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/